92 related articles for article (PubMed ID: 20438541)
21. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
Rostoker G; Griuncelli M; Loridon C; Couprie R; Benmaadi A; Bounhiol C; Roy M; Machado G; Janklewicz P; Drahi G; Dahan H; Cohen Y
Am J Med; 2012 Oct; 125(10):991-999.e1. PubMed ID: 22998881
[TBL] [Abstract][Full Text] [Related]
22. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection.
Stefánsson BV; Haraldsson B; Nilsson U
Free Radic Biol Med; 2008 Nov; 45(9):1302-7. PubMed ID: 18775775
[TBL] [Abstract][Full Text] [Related]
23. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes.
Van Campenhout A; Van Campenhout C; Lagrou A; Manuel-y-Keenoy B
Biometals; 2008 Apr; 21(2):159-70. PubMed ID: 17585373
[TBL] [Abstract][Full Text] [Related]
24. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
25. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
26. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
27. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
28. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430
[TBL] [Abstract][Full Text] [Related]
29. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
Espósito BP; Breuer W; Slotki I; Cabantchik ZI
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():42-9. PubMed ID: 11886431
[TBL] [Abstract][Full Text] [Related]
30. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
31. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
32. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
33. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study.
Mekki K; Bouchenak M; Remaoun M; Belleville JL
Med Sci Monit; 2004 Aug; 10(8):CR439-46. PubMed ID: 15277993
[TBL] [Abstract][Full Text] [Related]
34. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
Takeda Y; Komaba H; Goto S; Fujii H; Umezu M; Hasegawa H; Fujimori A; Nishioka M; Nishi S; Fukagawa M
Am J Nephrol; 2011; 33(5):421-6. PubMed ID: 21502756
[TBL] [Abstract][Full Text] [Related]
35. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
Driss F; Vrtovsnik F; Katsahian S; Michel C; Baron G; Kolta A; Sedrati N; Mentré F; Mignon F; Cabantchik I; Grandchamp B
Nephron Clin Pract; 2005; 99(3):c63-7. PubMed ID: 15640610
[TBL] [Abstract][Full Text] [Related]
36. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C.
Eiselt J; Racek J; Opatrný K; Trefil L; Stehlík P
Blood Purif; 2006; 24(5-6):531-7. PubMed ID: 17077626
[TBL] [Abstract][Full Text] [Related]
37. Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation.
Bnaya A; Shavit L; Malyszko JS; Malyszko J; Slotki I
Ther Apher Dial; 2020 Aug; 24(4):416-422. PubMed ID: 31762187
[TBL] [Abstract][Full Text] [Related]
38. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
[TBL] [Abstract][Full Text] [Related]
39. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM
Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901
[TBL] [Abstract][Full Text] [Related]
40. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
Parkkinen J; von Bonsdorff L; Peltonen S; Grönhagen-Riska C; Rosenlöf K
Nephrol Dial Transplant; 2000 Nov; 15(11):1827-34. PubMed ID: 11071973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
